Early 18F-FDG PET/CT Response Predicts Survival in Relapsed or Refractory Hodgkin Lymphoma Treated with Nivolumab

• DOI: 10.2967/jnumed.119.232827
• Publication Date: 2019-10-18T22:19:17Z
• Authors: Aiping Chen; Fatima-Zohra Mokrane; Lawrence H. Schwartz; Franck Morschhauser; Apasia Stamatoullas; Jean-Marc Schiano...; Laetitia Vercellino; Olivier Casasnovas; Adrien Chauchet; Alain Delmer; Emmanuelle Nicola...; Hervé Ghesquières; Marie-Pierre Mole...; Anna Schmitt; Rémy Dulery; Krimo Bouabdallah; Cecile Borel; Mohamed Touati; Benedicte Deau-Fi...; Frédéric Peyrade; Romain-David Seban; Guillaume Manson; Philippe Armand; Roch Houot; Laurent Dercle
• Keywords: Interquartile range; Refractory (planetary science); Complete response; Log-rank test

Monoclonal antibodies (mAbs) against programmed cell death 1 (PD-1), such as nivolumab and pembrolizumab, are associated with high response rates in patients relapsed or refractory classic Hodgkin lymphoma (HL). To date, no prognostic factor for overall survival (OS) has been established these agents HL. We examined whether the first early assessment evaluated using ¹⁸F-FDG PET/CT may be OS this setting. <b>Methods:</b> This retrospective study included 45 from 34 institutions. In a masked, centralized review, 3 independent radiologists classified scans obtained at median of 2.0 mo (interquartile range, 1.7–3.7 mo) after initiation existing criteria (i.e., 2014 Lugano classification 2016 LYRIC). Patients were according to 4 possible categories: complete metabolic (CMR), partial (PMR), (NMR), progressive disease (PMD). Because NMR PMR was similar, they grouped together. estimated Kaplan–Meier method compared between groups log-rank testing. <b>Results:</b> Eleven (24%) died follow-up 21.2 mo. The identical LYRIC because all 16 progression events indeterminate per confirmed on subsequent evaluations. Both CMR 13 cases (29%), PMD (36%), (9%), 12 (27%). 2-y probability significantly different (0.53; 95% confidence interval [95%CI], 0.32–0.87), (0.80; 95%CI, 0.63–1.00), (1.00; 1.00–1.00) population (<i>P</i> = 0.02, patients), well landmark analysis 0.05, 32 patients). <b>Conclusion:</b> HL treated anti-PD-1 mAbs, either predicted allowed risk stratification, suggesting that might used develop risk-adapted strategies.